DOAC promising for paediatric VTE

Treatment with bodyweight-adjusted rivaroxaban appears to be safe in children with acute VTE previously treated with low-molecular weight heparin, fondaparinux or a vitamin K antagonist, an Australian led study in Lancet Haematology finds. A phase 2 program of studies evaluating the DOAC in infants through to teenagers, used bodyweight-adjusted regimens that gave a similar rivaroxaban ...

Already a member?

Login to keep reading.

© 2021 the limbic